HistoIndex Extends Access To Its MASH Diagnostic Offering Through New Partnerships In Texas And California SINGAPORE, April 28, 2026 /PRNewswire/ — HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced the continued expansion of its commercial partnership network in the United States with the addition of two new hepatology and gastroenterology centers […]

HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services SINGAPORE, Jan. 21, 2026 /PRNewswire/ — HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced a strategic partnership with Houston Research Institute (HRI). HRI is a leading research institute focused on conducting clinical trials in hepatology and gastroenterology, with a

HistoIndex to Debut FibroSIGHT™ Plus and Showcase Latest Scientific Findings at AASLD The Liver Meeting® 2025 SINGAPORE, Oct. 15, 2025 /PRNewswire/ — HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, is returning to The Liver Meeting® (TLM) 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). The conference, which

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment SINGAPORE, Aug. 10, 2025 /PRNewswire/ — HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted

HistoIndex Secures SGD 9 Million Investment to Drive Next Phase of Expansion SINGAPORE, May 2, 2025 /PRNewswire/ — HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a S$9 million investment round to support its next

A New Standard in Clinical Care for MASH Patients: HistoIndex Launches FibroSIGHT™ SINGAPORE, March 17, 2025 /PRNewswire/ — HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHT™ – now available in the United States. This marks a significant milestone

BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL SINGAPORE, Dec. 9, 2024 /PRNewswire/ — A newly published collaborative study[1] in the Journal of Hepatology, featuring HistoIndex – a global leader in stain-free digital pathology solutions for managing fibrotic diseases – alongside Merck & Co., MSD, Virginia Commonwealth University (VCU), The National Institutes of Health (NIH) and a panel of distinguished international